Product Overview
Dragon Pharma Atorvastatin Calcium is a 40 mg oral tablet, and the pack contains a hundred of them. The molecule is a competitive inhibitor of HMG-CoA reductase, the enzyme that sets the pace of cholesterol synthesis in the liver. Blocking it lowers the cholesterol the liver makes, which in turn makes the hepatocyte display more LDL receptors on its surface, and those receptors clear LDL particles from circulation. That second step, not the enzyme block itself, is what produces most of the fall in LDL seen on a lipid panel.
The reason a statin appears in a bodybuilding catalogue is context rather than performance. Exogenous androgens, and especially oral ones, tend to depress HDL and raise LDL, so a user who is tracking bloodwork may see an unfavourable lipid profile while on a cycle such as Enantat 250 or a course built on Anavar 10. A statin addresses one number in that picture. It does not neutralise blood-pressure effects, haematocrit, clotting tendency or the hepatic strain of oral compounds, and treating it as a general safety net for a heavy cycle is a misunderstanding of what the drug does.
Absorption is fast and the liver does the rest; grapefruit and strong CYP3A4 inhibitors raise exposure, which is why the interaction list matters as much as the dose. Statins sit outside every anti-doping schedule, so there is no testing consequence attached, and the tablet needs no reconstitution or cold chain of any kind.
Dosage Protocol
The approved range runs from 10 to 80 mg a day. The steps below follow that label range and the practical convention of dosing in the evening, when cholesterol synthesis peaks; they are reference values, not a prescription, and the lipid panel is what decides the step.
| Beginner | 10 mg a day, the lowest step of the approved range, kept until a lipid panel says otherwise |
| Intermediate | 20 mg a day, usually for 4-12 weeks, taken in the evening |
| Advanced | 40-80 mg a day, only under medical direction, at the top of the labelled range |
| Female | 10-20 mg a day by lipid results; the label does not carry a separate female sports protocol, so none is invented here |
| Administration | Oral, once daily, at a fixed time; the 40 mg tablet is split when a lower step is wanted, and grapefruit or CYP3A4 inhibitors raise exposure |
The pack makes the lower steps easy to reach: a hundred tablets of 40 mg is a hundred days at full strength, or two hundred days when the same tablet is halved for someone sitting at 20 mg. Exposure is set by the liver rather than by the coating, because the parent drug clears in about fourteen hours while its active metabolites run for twenty to thirty, which is why one dose a day holds its effect around the clock. Evening intake follows the overnight peak in cholesterol synthesis rather than being a property of the tablet itself.
Suggested Protocols
Three arrangements cover how the tablet is used around a cycle. None of them has been tested as a combination in a trial, and every card opens the matching product page so the pieces can be assembled inside this section.
What to Expect
- Weeks 4-8. The first measurable LDL drop appears on a lipid panel here; testing sooner than four weeks tells you very little.
- Weeks 8-12. This is the usual window for judging the full effect and deciding whether the step should change.
- Muscle symptoms. Aches and cramps, when they happen, cluster in the first year of use and become more likely at higher doses and with interacting drugs.
- Liver enzymes. ALT and AST are checked before starting and during use, and a rise in transaminases is a reason to revisit the dose rather than to push on.
- The rare danger. Rhabdomyolysis is extremely uncommon but serious, and severe muscle pain with dark urine means stopping immediately and seeking care.
- Interactions. Grapefruit and strong CYP3A4 inhibitors lift blood levels of the drug, sometimes substantially.
- What it is not. A statin corrects one lipid marker; it does not make a hepatotoxic or cardiovascular-heavy cycle safe.
Side Effects and Management
Most users tolerate the tablet without incident, and the serious events are rare. The list below reflects label-level and class-level information rather than rates measured for this pack.
Monitoring and Cycle Support
A statin does not suppress the gonadal axis, so no post-cycle restart is needed and this product is not a recovery drug. What it does demand is a monitoring routine, because the useful decisions are made from numbers.
The practical partner list is short. Oral 17-alpha-alkylated products such as Winstrol 10 load the same organ the statin works through, so combining them raises the monitoring requirement rather than lowering it. When a cycle ends and the question turns to restoring natural output, the tools are Nolvadex or Clomid, and estrogen control runs on Aromasin only when bloodwork justifies it. None of those changes the statin schedule, and the statin does not remove the need for any of them.
